Emerging evidence · Grade B
Kisspeptin-10
Hormone Optimization
Score
66 / 100
Class
Reproductive neuropeptide
Role
GnRH axis 'master switch'
Status
Investigational
TL;DR
01
The short active fragment of kisspeptin, a 'master switch' neuropeptide that sits at the very top of the reproductive hormone axis, telling the brain to start the cascade that drives fertility.
02
The strongest human evidence is actually for the longer isoform, kisspeptin-54, which triggered egg maturation in IVF and led to successful pregnancies.
03
It is genuinely promising in reproductive medicine — as a gentler ovulation trigger and in hypothalamic amenorrhea and sexual-response research.
04
But it is investigational: no approved product, kisspeptin-10 has a very short half-life, and its trendier 'libido' marketing outruns the reproductive-endocrine evidence.
05
Consumer 'kisspeptin-10' is research-grade and unregulated.
Strongest human data
Kisspeptin-54
IVF egg-maturation trigger
Kisspeptin-10 half-life
Very short
minutes
Research uses
Fertility, amenorrhea
+ sexual-response studies
Approved product
None
investigational
Libido marketing
Ahead of evidence
reproductive data is the base
Part 01 · How it works
Mechanism.
Kisspeptin sits at the top of the chain that controls reproduction: it tells the hypothalamus to release GnRH, which triggers the pituitary to release LH and FSH, which act on the ovaries or testes. Because it works one step upstream, researchers have used it as a gentler, more physiologic way to trigger egg maturation in IVF — and it worked, producing pregnancies. Most of that strong human data used the longer kisspeptin-54; the shorter kisspeptin-10 sold to consumers has a very brief duration and a thinner evidence base, especially for the libido claims it's often marketed on.
The 'ignition key' for the whole reproductive hormone engine. Turning it works — best shown with the longer-lasting version in fertility clinics; the short consumer fragment is a weaker, briefer version of that key.
KISS1R agonism
Activates the kisspeptin receptor on GnRH neurons, driving GnRH → LH/FSH release — the top of the reproductive axis.
Physiologic trigger
Used to induce a physiologic LH surge/egg maturation in IVF (kisspeptin-54), with a lower OHSS risk profile under study.
Isoform/half-life
Kisspeptin-10 is the short active fragment with a very short half-life; kisspeptin-54 carries most of the clinical data.
Evidence stage
Investigational; real reproductive-medicine trials; behavioral/libido uses less established.
Part 02 · Dosing & administration
How it's taken.
Clinical · trial-validatedValues below describe how Kisspeptin-10 has been administered in human clinical trials and/or approved labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Research
Weight-based (SC)
Trial dosing (e.g., kisspeptin-54 as an IVF trigger); no approved consumer regimen.
·
Any doses referenced are from research trials, not instructions.
·
Kisspeptin-10's short half-life limits practical dosing; trials often used kisspeptin-54.
·
No approved product; consumer supply is research-grade.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Injection-site reactions
Generally mild in trials.
Reported
Flushing
Transient.
Occasional
Serious · rare
Reproductive-hormone effects
Directly stimulates the reproductive axis; unsupervised use is unpredictable.
Expected
Product-quality risk
Research-grade supply may not match labeled purity/dose.
Source-dependent
Absolute · do not use
×
Hormone-sensitive cancers (breast, prostate, ovarian, endometrial)
×
Pregnancy or breastfeeding
×
Children under 18 (except under endocrinology specialist care for pubertal disorders)
×
Known hypersensitivity to kisspeptin or any component
×
Undiagnosed abnormal uterine bleeding
Relative · discuss first
!
Pregnancy or hormone-sensitive conditions — reproductive-axis stimulation
!
Fertility treatment outside a monitored program — unpredictable effects
!
Expecting a proven libido benefit — evidence is limited
!
Anyone seeking an approved product — it is investigational
Interactions
GnRH agonists/antagonists (leuprolide, cetrorelix)
Kisspeptin stimulates GnRH release; may interfere with or potentiate GnRH-based therapies
Major
Hormonal contraceptives
Kisspeptin stimulates gonadotropin release which may reduce contraceptive efficacy
Moderate
Testosterone or estrogen replacement
Kisspeptin stimulates endogenous sex hormone production; may lead to supraphysiologic levels
Moderate
Labs to monitor
LH and FSH
Baseline and per protocol
Kisspeptin directly stimulates GnRH and gonadotropin release
Total and Free Testosterone (men) or Estradiol (women)
Baseline and per protocol
Downstream hormonal effects
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
General metabolic safety
Prolactin
Baseline
HPG axis modulation can affect prolactin
Part 04 · Evidence
How strong is the evidence?
66
Grade B
Grade B, Emerging. Kisspeptin has genuine, high-quality reproductive-medicine human data (mostly as kisspeptin-54) and a compelling mechanism, but it is investigational, the consumer kisspeptin-10 fragment is short-acting, and its libido marketing outpaces the evidence.
Mechanistic plausibility
Master regulator of the reproductive axis; mechanism very well established.
85
Human evidence
Strong IVF-trigger trials (kisspeptin-54); less for kisspeptin-10 specifically and for behavioral uses.
62
Safety & tolerability
Well tolerated in trials; potentially lower OHSS risk as a trigger; long-term data limited.
70
Durability
Very short half-life for kisspeptin-10; effects are acute.
55
Independence
Academic (Imperial/Dhillo) trial program; independent of consumer marketing.
66
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2014
J Clin Invest Flagged
Kisspeptin-54 triggers egg maturation in women undergoing IVF
A single subcutaneous dose of kisspeptin-54 induced an LH surge and egg maturation; 92% had eggs fertilized and embryos transferred, with 23% clinical pregnancy — a genuine human reproductive-medicine result.
Dose-ranging clinical trial · n = 53 · Uses kisspeptin-54 (not the marketed kisspeptin-10); strong proof-of-concept.
PMID 25036713 ↗
Moderate-High
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
The strong data is kisspeptin-54, not the marketed kisspeptin-10
Mechanism limit J Clin Invest · 2014
The impressive human reproductive results largely used kisspeptin-54. The consumer-marketed kisspeptin-10 is a shorter fragment with a very brief half-life and less direct clinical evidence.
What this means: Citing 'kisspeptin fertility trials' to sell kisspeptin-10 conflates two related but different molecules. The short fragment's own evidence is thinner.
PMID 25036713 ↗
02
Libido/behavioral marketing outruns the evidence
Mechanism limit reproductive-endocrine context · 2014
Kisspeptin's robust evidence is in reproductive endocrinology (ovulation triggering, amenorrhea). Its trendier marketing for libido/sexual enhancement is based on early, limited studies, not established outcomes.
What this means: It is a serious reproductive-medicine investigational agent, not a proven libido supplement. Treat the sexual-enhancement claims as unproven.
Part 06 · Cost & access
Where it's available, at what price.
United States
Investigational
Not approved; used in research. Consumer kisspeptin-10 is research-grade.
Grey-market; unregulated
European Union
Investigational
Not approved; research use.
N/A
United Kingdom
Investigational
Active academic research (e.g., Imperial College); not an approved consumer product.
Research setting
Canada
Investigational
Not approved.
N/A
The Peptide Column takes no affiliate commission from any source. Kisspeptin is an investigational reproductive-medicine agent, not an approved product; consumer kisspeptin-10 is research-grade and unregulated, and its libido marketing is not evidence-based. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
Could kisspeptin help diagnose or treat my reproductive hormone issues?
02
How does kisspeptin compare to HCG or clomiphene for stimulating natural testosterone?
03
Is kisspeptin being used as an IVF trigger at any clinics?
04
What are the potential benefits of kisspeptin for libido and sexual function?
05
Is kisspeptin therapy available, or is it still primarily investigational?
06
Would kisspeptin be appropriate for recovering my HPG axis after steroid use?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. Kisspeptin-54 triggers egg maturation in women undergoing IVF · J Clin Invest, 2014 · PMID 25036713 ↗
- 02. Imperial College London. Dhillo group kisspeptin reproductive trials